{"entity":{"id":"bcd-217","kind":"drug","name":"BCD-217","aka":["nurulimab+prolgolimab"],"tldr":"BCD-217 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, aimed at PD-1 and CTLA-4.","summary":"BCD-217 is an investigational agent whose form is not stated in the registry developed by Biocad. Its targets are PD-1 and CTLA-4. ClinicalTrials.gov describes the intervention as: Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma) and NCT05751928 (A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma), in melanoma. The largest, NCT05751928, plans to enrol 411 participants (actual) with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of BCD-217","url":"https://clinicaltrials.gov/search?intr=BCD-217"},{"label":"Sponsor page","url":"https://biocad.ru/products"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["pd1","ctla4"],"drugs":[],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05732805","nct05751928"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)","mechanism":"Investigational agent whose form is not stated in the registry directed at PD-1 and CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bcd-217/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}],"trial":[{"id":"nct05732805","kind":"trial","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","route":"/trials/nct05732805/"},{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/"}]}}